Therapeutic Solutions International Inc (TSOI)

[cablejohn]

ARDScells Phase 3 ----NEW!
Phase IIb/III Trial of Umbilical Cord-derived Mesenchymal Stem Cells for Patients with Acute Respiratory Distress Syndrome
(IIb/III UC-MSCs for ARDS)

This is a double-blind, phase 2b/3, randomized, controlled, multi-center trial of 128 subjects with moderate to severe ARDS. Allocation to UC- MSC treatment group or control group will be based on 1:1 randomization: 64 subjects will be allocated to UC-MSC treatment group, 64 subjects to control group. Randomization will be stratified by site and by type of oxygen therapy (High Flow Oxygen/NIPPV versus mechanical ventilation). The study will test the hypothesis that UC-MSC treatment leads to an increase of the proportion of patients alive and free of respiratory failure at day 60 after randomization. The study will also estimate effects on survival, on the occurrence of Serious Adverse Events (SAEs), and on time to recovery.

REDUCTION OF NEUTROPHIL EXTRACELLULAR TRAP FORMATION BY MESENCHYMAL STEM CELLS AND THEIR EXOSOMES
Publication number: 20230107484

Abstract: Disclosed are methods of reducing lung inflammation in acute respiratory distress syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.

https://therapeuticsolutionsint.com/pipeline/